SZABO SCANDIC

Part of Europa Biosite

Produktinformation

- Forschungsprodukte & Biochemikalien
- Zellkultur & Verbrauchsmaterial
- Diagnostik & molekulare Diagnostik
- Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!

Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic

Tunicamycin V

Cat. No.:	HY-N8395
CAS No.:	66054-36-2
Molecular Formula:	$C_{39}H_{64}N_4O_{16}$
Molecular Weight:	844.94
Target:	Bacterial
Pathway:	Anti-infection
Storage:	Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month



BIOLOGICAL ACTIVITY

Description	Tunicamycin V (Tunicamycin A) is a nucleoside natural product that inhibits bacterial phospho-N-acetylmuramyl-pentapeptide transferase (MraY) with an IC_{50} of 0.35 μM. Tunicamycin V has antibacterial activties[1][2].
IC_{50} & Target	IC50: 0.35 μM (phospho-N-acetylmuramyl-pentapeptide transferase (MraY))[1]
In Vitro	Tunicamycins are nucleoside natural products isolated from the fermentation broths of Streptomyces lysosuperficus in 1971 and exhibit a variety of biological properties including antibacterial, antiviral, antifungal, and antitumor activities. Tunicamycins strongly inhibit UDP-N-acetylglucosamine (GlcNAc): polyprenol phosphate translocase, the enzyme responsible for the first N-acetylglucosamination of the N-linked glycopeptide in endothelial reticulum (ER)[2]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

CUSTOMER VALIDATION

- Cancer Lett. 2021 Jun 18.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Kazuki Yamamoto, et al. Structural requirement of tunicamycin V for MraY inhibition. Bioorg Med Chem. 2019 Apr 15;27(8):1714-1719.

[2]. Kazuki Yamamoto, et al. Total Synthesis of Tunicamycin V. Org Lett. 2018 Jan 5;20(1):256-259.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA